GlassScriptPhysician profile
Mary Lee
NPI 1194277244
$10,753.83
in general payments reported to CMS, 2019-2025
15 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,267 · 2022: $1,857 · 2023: $2,556 · 2024: $2,616 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,814 · Consulting Fee: $740 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,814.20 |
| Consulting Fee | $740.00 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,097.06 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,985.66 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,492.58 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,076.29 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $944.26 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $821.72 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $807.57 | 2021-2024 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $416.04 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $384.80 | 2021-2022 | |
| Lundbeck LLC | $232.24 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $194.09 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $123.22 | 2023-2024 | Auvelity |
| Indivior INC. | $105.74 | 2023-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $55.52 | 2021-2022 | |
| Abbott Laboratories | $17.04 | 2025 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.